11 10:50-11: :15-11:40 R 3 11:40-12:20, 4 15:10-15:50 ips 13 15:50-16:15 in vitro 14 16:15-16: :40-17: :05-17: :30-17:55

Size: px
Start display at page:

Download "11 10:50-11: :15-11:40 R 3 11:40-12:20, 4 15:10-15:50 ips 13 15:50-16:15 in vitro 14 16:15-16: :40-17: :05-17: :30-17:55"

Transcription

1 (*Outstanding Poster Presentation ) 1F 12 14, 1 10:30-10: :55-11: :20-11: :15-16: :40-17: :05-17:30 RNA ips 8 17:30-17: :45-12:25 MEMS, 2 15:10-15:50 UT-Heart 4 15:50-16: , 9 10:00-10: :25-10:50

2 11 10:50-11: :15-11:40 R 3 11:40-12:20, 4 15:10-15:50 ips 13 15:50-16:15 in vitro 14 16:15-16: :40-17: :05-17: :30-17:55 10, 13:00-14:40 2F :00-13:40 13:40-14:10 14:10-14:40 1A I *1A01 (), ( ), () *1A02 (),,, *1A03 FRET (), ( ), (),, (),, ( ), (), () *1A04 (),,, *1A05 PKCα (),, 1A06 () *1A07 (), 1A08 Nesprin (),, (),, ()

3 1A09 (),, *1A10 (), 1A11 (),, *1A12 (), *1A13 (),, 1A14 (),, *1A15 *1A16 (),,,, *1A17 *1A18 (),,, *1A19 (), 1B *1B01 T1-S2 (),,, (), *1B02 (),,, ( ), 1B03 (), (), (), *1B04 (),,, (),, *1B05 3 (), Debski Richard (), () *1B06 (), ( ), (), (),, () *1B07 (),,, (), *1B08 (),,, (), ( ), *1B09 (),,, *1B10 *1B11 (),,,, *1B12 : (),,,,,,, (), ( ) *1B13 (),,, *1B14 (/ ), ( ), (), ( )

4 *1B15 (),, (), (), *1B16 () (),, *1B17 2 in vivo (),,,, (),, *1B18 6 (),, (), () *1B19 (DPOAEs) : (), *1B20 (),, 1C *1C01 (),, *1C02 (),, *1C03 (), Tran Van Thuc, Dao Quy Thinh,,,, (), () *1C04 (),,,, ( ), () *1C05 (), Dao Quy Thinh, Tran Van Thuc,,,, ( ), () *1C06 (),, *1C07 (), Mohd Ramli Nur Fatin Fatina, *1C08 (),,,,,, *1C09 / (),, *1C10 (),, *1C11 (), ( ),, ( ), () *1C12 (),, *1C13 (),, () *1C14 in silico (),, (), () 1C15 (), *1C16 (),, ()

5 *1C17 (), (), (), () *1C18 - (), (),, () *1C19 CT MRI (),,,, *1C20 (),,, 1D01 1D02 1D03 1D (),, () (),,,, (), () (),,,, (), () *1D04 (),, (),, *1D05 Karimi Alireza(),, *1D06 (),,, () *1D07 (),, *1D08 *1D09 (),, *1D10 FEM (),, *1D11 A (),, *1D12 (),, *1D13 (),, *1D14 (),, 1D15 1D16 (),, (), (), ( ), () 1E I *1E01 MRI (),, (), ( ), (), () *1E02 Time SLIP MRI (),, (), (), ( ) *1E03 (),,

6 *1E04 (),, *1E05 (),, *1E06 (),,, *1E07 (), ( ), (),, (), () *1E08 (), (), (), () 1E09 (),,,, *1E10 (),, 1F01 1F I () *1F02 (), *1F03 (), *1F04 (),, *1F05 (), *1F06 (),, *1F07 (),, *1F08 in vitro (),, *1F09 (),,,, *1F10 (),, *1F11 (),, (), *1F12 (), (), (), *1F13 (),, (), () 1F14 (/ ), () *1F15 (),, *1F16 (), *1F17 2 (),,, *1F18 (),,

7 *1F19 FMD (),, (), () *1G11 (),,,, *1F20 (), 1G12 Creek-Gap (),, (), () 1G *1G01 (), *1G02 (),,, *1G03 (),,, 1G04 (), *1G05 SAM (),,,, *1G06 Aqueous Two-Phase System(ATPS) (),,,, *1G07 (),,, *1G08 (),, *1G09 (),,, *1G10 (), ( /EBM), (), *1G13 (),,,, (), *1G14 mes (),, *1G15 Differentiation control of mesenchymal stem cells on nanoscale check-patterned surface (),, Montagne Kevin,, *1G16 (),,, *1G17 (),, *1G18 (),, *1G19 (), 1G20 1H01 (), (), Lei Wu(), Arifin Izzuddin, 1H I (), (),, (), (), ()

8 *1H02 (),, (), (), (), () *1H03 FEM (), Mani Ganesh Kumar, *1H04 (),, *1H05 (), ( ),,,, (),, ( ) 1H06 (), ( ), (),,, (), ( ),, () *1H07 VA (),, *1H08 (),,,,,,, 1H09 (), (),, (),,, *1H10 (),, (), () *1H11 (),,,,,,, (), () *1H12 (),,,,,,, (), () *1H13 (), *1H14 (),,, (), ( ),, (),,, (), () 1H15 (),,,,, *1H16 (),,, *1H17 (),, *1H18 (),, (),, (), (), () *1H19 (),, (),,, (), *1H20 - (),,, 1I *1I01 (),, *1I02 (),

9 *1I03 (),, *1I04 (), *1I05 (),, *1I06 (),,, (), 1I07 (), *1I08 (),, Nix Stephanie *1I09 (),,, *1I10 (),,, *1I11 ATP (),,,,,,, (),,, () *1I () *1I13 (),,, *1I14 (),,,,,, (), () *1I15 (),,,,,,,, (), (), () *1I16 (), *1I17 (),,,, (), () *1I18 2 (), *1I19 (),,, 2A :00-13:40 13:40-14:10 14:10-14:40 2A II (), *2A02 (),,, *2A03 (),,,

10 2A04 (),,,, *2A05 (), *2A06 (),,,, *2A07 (),, 2A17 2A18 (), (),, (KAIST), () *2A19 (),,, 2B III *2A08 (),, 2B01 (), *2A09 (),, (), () *2A10 (),,, *2A11 (), *2A12 (),,,,, 2A13 RNA mir-155 (),, *2A14 (),,, *2A15 glioblastoma (),, *2A16 (), *2B02 (), () *2B03 (),, 2B04 (), () *2B05 CT-based (),, *2B06 (),,,, (/EBM), (), *2B07 (),,, *2B08 (), ( ), () 2B09 (), (), (),, ()

11 *2B10 (), *2B11 DNA (),, *2B12 DNA (), () 2B13 2B14 CHO (), ( ) () *2B15 (),,, *2B16 (), (), () *2B17 β- (), *2B18 (),,, *2B19 ( ) (), 2C *2C01 (),,,,,, *2C02 (),, 2C03 (),,,,, *2C04 (),,,,, *2C05 (),,,,,,, (), ( ), 2C06 (), Warner Mia(Clemson Univ), (),, *2C07 (),,,,,,, *2C08 (),,,,,,, *2C09 *2C10 Rollover (),,, *2C11 (),,, 2C12 (), (), () *2C13 6- strands (),,, (),, (),, *2C14 (),

12 *2C15 (),,, *2C16 (),,, (),, *2C17 (), 2C18 (),, () *2C19 (),,, () 2D *2D01 (), *2D02 (),, *2D03 (),, 2D04 (),,, *2D05 (),, *2D06 (),,, () *2D08 (),,, () *2D09 (),, *2D10 (),,,, 2D11 ICF-CY (),,,,, *2D12 (),,,, ( /), () *2D13 (),,, *2D14 (),, *2D15 (),, (), ( ), ( ), () 2D16 2D17 (TOTO),, (), (), (),,, () *2D18 (),,, *2D07 (), ( ), () 2D19 (),

13 2D20 (),, 2E II *2E01 (),, *2E02 (),, *2E03 Guyot Yann(), *2E04 in vivo (),,, (), (),,,, (),, ( ) *2E05 *2E06 (),, *2E07 : (),,,,, 2E08 2E09 (),,,, (), ( ), *2E10 SHG() (), ( 8), (/), (), 2F II *2F01 (),,, *2F02 (),, (), () *2F03 (),,, *2F04 (),, (), () *2F05 (),,,, *2F06 (),, 2F07 (), ( ), () *2F08 (), *2F09 2 (), 2F10 (),, *2F11 (),,,, *2F12 (),,,,,

14 *2F13 PDMS HL-60 (P- ) (),,Rieu Jean-Paul() *2F14 (), *2F15 (),, *2F16 (),,,, (), () *2F17 (),,, (), (British Columbia Children s Hospital), () *2F18 (), ( ), () *2F19 (),, Ku David(Georgia Tech) *2F20 Hanai (),,, 2G01 2G RE- DEEM 15 (), *2G02 (),, (), (),, *2G03 (),, (), () *2G04 (),,,,, Pramudita Jonas A, *2G05 (), ( ), (), *2G06 (), *2G07 (),,,, *2G08 (), Oo Maung Chit,, (), () 2G09 Optical Coherence Straingraphy 3 (),,, *2G10 (),,, (), (), *2G11 (),,, *2G12 ips (),,, (/), (),,, () *2G13 (/),,,, ( ), ()

15 *2G14 (),,,, *2G15 Scaffold-Free Tissue (), Jeonghyun Kim,,, (),, (),, *2G16 (),,, *2G17 (), *2G18 (),,, 2G19 (),,,,, ( ), () *2G20 (/),,, (/), (),,, (), () 2H II *2H01 (),, *2H02 (),,, (), (),, (), (), () *2H03 Organ-on-a-chip (), ( ), (), (), *2H04 Zhu Jing(),, *2H05 (), (), () *2H06 (), (), (), () *2H07 (),,,,,,, *2H08 UHMWPE (),,, (),, (), *2H09 RGDS / (),,,,,,, *2H10 RGDS (),,,,, *2H11 Destruction Energy Index - (),,,,,, *2H12 (), *2H13 (),,,,,,, *2H14 PCL (),,

16 *2H15 MgSiO3 (),,, *2H16 (),, *2H17 HAp/ (),, *2H18 (),,, *2H19 HAp/PLA (),, *2H20 (),,, 2I06 (), (), (), ( ), () Optical Coherence Doppler Velocigraphy 3 in vivo (),,, (),,, (), *2I07 ( ), ( ), (British Columbia Children s Hospital),Barker Alex(Northwestern University), () 2I08 3 () *2I09 (), (Johns Hopkins Univ), () 2I01 2I (), 2I10 (),,,,,,, *2I02 PVA-H (),Tupin Simon, (), () 2I03 (), ( ) *2I04 ( ) (),, (), (), (), ( ), () *2I05 ( ) (),, (), (),,

4 15:10-15:50 ips 13 15:50-16:15 in vitro 14 16:15-16: :40-17: :05-17: :30-17:55 10, (), ( ), () *1A02 (),,, *1A03 FRET (), (),

4 15:10-15:50 ips 13 15:50-16:15 in vitro 14 16:15-16: :40-17: :05-17: :30-17:55 10, (), ( ), () *1A02 (),,, *1A03 FRET (), (), (*Outstanding Poster Presentation ) 1F 12 14 1 10:30-10:55 2 10:55-11:20 3 11:20-11:45 1 11:45-12:25 MEMS 2 15:10-15:50 UT-Heart 4 15:50-16:15 5 16:15-16:40 6 16:40-17:05 7 17:05-17:30 RNA ips 8 17:30-17:55

More information

BE17Prog161015

BE17Prog161015 全体タイムテーブル 2017 年 1 月 19 日 ( 木 ) A 室 B 室 C 室 D 室 E 室 F 室 G 室 9:00 9:15 細胞のバイオメカニ 9:30 クス メカノバイオロ循環器系のバイオメ OS: スキンメカニク 9:45 ジー : 力とシグナル伝人工臓器 : 人工心カニクス : 赤血球流硬組織のバイオメカスの評価と展開 (1) 10:00 達臓 体外循環れバイオロボティクスニクス

More information

1 911 9001030 9:00 A B C D E F G H I J K L M 1A0900 1B0900 1C0900 1D0900 1E0900 1F0900 1G0900 1H0900 1I0900 1J0900 1K0900 1L0900 1M0900 9:15 1A0915 1B0915 1C0915 1D0915 1E0915 1F0915 1G0915 1H0915 1I0915

More information

1 (1) (2)

1 (1) (2) 1 2 (1) (2) (3) 3-78 - 1 (1) (2) - 79 - i) ii) iii) (3) (4) (5) (6) - 80 - (7) (8) (9) (10) 2 (1) (2) (3) (4) i) - 81 - ii) (a) (b) 3 (1) (2) - 82 - - 83 - - 84 - - 85 - - 86 - (1) (2) (3) (4) (5) (6)

More information

- 2 -

- 2 - - 2 - - 3 - (1) (2) (3) (1) - 4 - ~ - 5 - (2) - 6 - (1) (1) - 7 - - 8 - (i) (ii) (iii) (ii) (iii) (ii) 10 - 9 - (3) - 10 - (3) - 11 - - 12 - (1) - 13 - - 14 - (2) - 15 - - 16 - (3) - 17 - - 18 - (4) -

More information

2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1

2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1 1 1979 6 24 3 4 4 4 4 3 4 4 2 3 4 4 6 0 0 6 2 4 4 4 3 0 0 3 3 3 4 3 2 4 3? 4 3 4 3 4 4 4 4 3 3 4 4 4 4 2 1 1 2 15 4 4 15 0 1 2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4

More information

20 15 14.6 15.3 14.9 15.7 16.0 15.7 13.4 14.5 13.7 14.2 10 10 13 16 19 22 1 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 2,500 59,862 56,384 2,000 42,662 44,211 40,639 37,323 1,500 33,408 34,472

More information

I? 3 1 3 1.1?................................. 3 1.2?............................... 3 1.3!................................... 3 2 4 2.1........................................ 4 2.2.......................................

More information

II. b 睞 c. 57

II. b 睞 c. 57 II. 1. 2 2. 1 2 1 a. b. c. d. e. 2 a. b. 2-1. a. 56 II. b. 1940 9 4 1940 9 4 1940 9 4 3 1 1940 7 8 30 2 8 3 9 4 9 22 睞 1940 9 4 c. 57 4 1 2 3 4 1943 5 29 58 II. d. 3 1 2 3 59 e. 1945 3 12 9 2 1 1945 2

More information

研修コーナー

研修コーナー l l l l l l l l l l l α α β l µ l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l

More information

nsg02-13/ky045059301600033210

nsg02-13/ky045059301600033210 φ φ φ φ κ κ α α μ μ α α μ χ et al Neurosci. Res. Trpv J Physiol μ μ α α α β in vivo β β β β β β β β in vitro β γ μ δ μδ δ δ α θ α θ α In Biomechanics at Micro- and Nanoscale Levels, Volume I W W v W

More information

44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)

44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2) (1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46

More information

i ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii

More information

1 10 1113 14 1516 1719 20 21 22 2324 25 2627 i 2829 30 31 32 33 3437 38 3941 42 4344 4547 48 4950 5152 53 5455 ii 56 5758 59 6061 iii 1 2 3 4 5 6 7 8 9 10 PFI 30 20 10 PFI 11 12 13 14 15 10 11 16 (1) 17

More information

..0.._0807...e.qxp

..0.._0807...e.qxp 4 6 0 4 6 0 4 6 8 30 34 36 38 40 4 44 46 8 8 3 3 5 4 6 7 3 4 6 7 5 9 8 3 4 0 3 3 4 3 5 3 4 4 3 4 7 6 3 9 8 Check 3 4 6 5 3 4 0 3 5 3 3 4 4 7 3 3 4 6 9 3 3 4 8 3 3 3 4 30 33 3 Check Check Check Check 35

More information

h01

h01 P03 P05 P10 P13 P18 P21 1 2 Q A Q A Q A Q A Q A 3 1 check 2 1 2-1 2-2 2-3 2-4 2-5 2-5-1 2-6 2-6-1 2-6-2 2-6-3 3 3-1 3-2 3-3 3-4 3 check 4 5 3-5 3-6 3-7 3-8 3-9 4-1 4-1-1 4-2 4-3 4-4 4-5 4-6 5-1 5-2 4

More information

1 2 3 4 1 2 1 2 3 4 5 6 7 8 9 10 11 27 29 32 33 1 2 3 7 9 11 13 15 17 19 21 23 26 CHECK! 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1

More information

001 No.3/12 1 1 2 3 4 5 6 4 8 13 27 33 39 001 No.3/12 4 001 No.3/12 5 001 No.3/12 6 001 No.3/12 7 001 8 No.3/12 001 No.3/12 9 001 10 No.3/12 001 No.3/12 11 Index 1 2 3 14 18 21 001 No.3/12 14 001 No.3/12

More information

tokutoku.pdf

tokutoku.pdf 1 2 MIYAGI CHILDRENʼS HOSPITAL 3 MIYAGI CHILDRENʼS HOSPITAL 4 5 MIYAGI CHILDRENʼS HOSPITAL 6 MIYAGI CHILDRENʼS HOSPITAL 7 MIYAGI CHILDRENʼS HOSPITAL 8 MIYAGI CHILDRENʼS HOSPITAL 9 MIYAGI CHILDRENʼS HOSPITAL

More information

01

01 2 0 0 7 0 3 2 2 i n d e x 0 7. 0 2. 0 3. 0 4. 0 8. 0 9. 1 0. 1 1. 0 5. 1 2. 1 3. 1 4. 1 5. 1 6. 1 7. 1 8. 1 9. 2 0. 2 1. 2 3. 2 4. 2 5. 2 6. O k h o t s k H a m a n a s u B e e f 0 2 http://clione-beef.n43.jp

More information

EV200R I II III 1 2 3 4 5 6 7 8 9 10 1 2 3 11 4 5 12 6 13 1 2 14 3 4 15 5 16 1 2 17 3 18 4 5 19 6 20 21 22 123 456 123 456 23 1 2 24 3 4 25 5 3 26 4 5 6 27 7 8 9 28 29 30 31 32 1 2 33 3 4 34 1 35 2 1

More information

(2009) 1... / 1 ( ) / 1 ( ) / 1 ( ), 2 ( )

(2009) 1... / 1 ( ) / 1 ( ) / 1 ( ), 2 ( ) 212009................................................ 2............................................ 115 (2009) 1... / 1 ( )........................................... 4 2... / 1 ( )......................................

More information

23 15961615 1659 1657 14 1701 1711 1715 11 15 22 15 35 18 22 35 23 17 17 106 1.25 21 27 12 17 420,845 23 32 58.7 32 17 11.4 71.3 17.3 32 13.3 66.4 20.3 17 10,657 k 23 20 12 17 23 17 490,708 420,845 23

More information

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 ( ) 24 25 26 27 28 29 30 ( ) ( ) ( ) 31 32 ( ) ( ) 33 34 35 36 37 38 39 40 41 42 43 44 ) i ii i ii 45 46 47 2 48 49 50 51 52 53 54 55 56 57 58

More information

untitled

untitled i ii (1) (1) (2) (1) (3) (1) (1) (2) (1) (3) (1) (1) (2) (1) (3) (2) (3) (1) (2) (3) (1) (1) (1) (1) (2) (1) (3) (1) (2) (1) (3) (1) (1) (1) (2) (1) (3) (1) (1) (2) (1) (3)

More information

平成18年度「商品先物取引に関する実態調査」報告書

平成18年度「商品先物取引に関する実態調査」報告書 ... 1.... 5-1.... 6-2.... 9-3.... 10-4.... 12-5.... 13-6.... 15-7.... 16-8.... 17-9.... 20-10.... 22-11.... 24-12.... 27-13... 29-14.... 32-15... 37-16.... 39-17.... 41-18... 43-19... 45.... 49-1... 50-2...

More information

訪問看護ステーションにおける安全性及び安定的なサービス提供の確保に関する調査研究事業報告書

訪問看護ステーションにおける安全性及び安定的なサービス提供の確保に関する調査研究事業報告書 1... 1 2... 3 I... 3 II... 3 1.... 3 2....15 3....17 4....19 5....25 6....34 7....38 8....48 9....58 III...70 3...73 I...73 1....73 2....82 II...98 4...99 1....99 2....104 3....106 4....108 5.... 110 6....

More information

›ïŁñ43-2†iHPŠp†j

›ïŁñ43-2†iHPŠp†j 40 40 40 5 http://maku-jp.org/ 2018 5 8 9 63 DDS 1 8,000 3,000 11,000 9,000 3,000 12,000 30,000 5 3,000 30 2 2018 5 8 18 00 63 1 6,000 3 2018 4 6 019 0116521 0961801 40 63 JR 15 JR 12 3 15 86 77 71 3 40

More information

(個別のテーマ) 薬剤に関連した医療事故

(個別のテーマ) 薬剤に関連した医療事故 - 67 - III - 68 - - 69 - III - 70 - - 71 - III - 72 - - 73 - III - 74 - - 75 - III - 76 - - 77 - III - 78 - - 79 - III - 80 - - 81 - III - 82 - - 83 - III - 84 - - 85 - - 86 - III - 87 - III - 88 - - 89

More information

(個別のテーマ) 放射線検査に関連した医療事故

(個別のテーマ) 放射線検査に関連した医療事故 - 131 - III - 132 - - 133 - III - 134 - - 135 - III - 136 - - 137 - III - 138 - - 139 - III - 140 - - 141 - III - 142 - - 143 - III - 144 - - 145 - III - 146 - - 147 - III - 148 - - 149 - III - 150 - -

More information

i

i 14 i ii iii iv v vi 14 13 86 13 12 28 14 16 14 15 31 (1) 13 12 28 20 (2) (3) 2 (4) (5) 14 14 50 48 3 11 11 22 14 15 10 14 20 21 20 (1) 14 (2) 14 4 (3) (4) (5) 12 12 (6) 14 15 5 6 7 8 9 10 7

More information

08-02 生命の定義と遺伝.pptx

08-02 生命の定義と遺伝.pptx 1 2 (1) (2) (3) (1) (2) DNA (3) (4) (ATP) Richard Dawkins () DNARNA () ( ) ( ) 1 2 2 1 heredity inheritance (Genetics) 1865 (1909 - - - DNA Molecular Genetics 1920 1953 ) 1. (P) (F1) (F2) 2. 1 2 3 web

More information

5 ex. neo^r ex. P. ips induced Pluripotent Stem cells 4 ES ex. ex. DNA

5 ex. neo^r ex. P. ips induced Pluripotent Stem cells 4 ES ex. ex. DNA 4 MZ DZ MZ DZ ex.mz 0.8 DZ 0.4 2 ex. 0.8 ex. MZ 0.8 DZ 0.6 ex. MZ 0.8 DZ 0.1 E LDL E2 E3 E4 128 152 E2 CC E3 CR E4 RR 10 ex. G6PD CYP CYP P CYP CYP CYP3 CYP CYP 5 ex. neo^r ex. P. ips induced Pluripotent

More information